Condition: Autoimmune Rheumatic Diseases · Sponsor: University of Sao Paulo General Hospital
This interventional phase IV clinical trial will evaluate the efficacy, immunogenicity and safety of the adjuvanted recombinant herpes zoster vaccine (RZV) in adults with autoimmune rheumatic diseases (ARDs) receiving immunomodulatory monotherapy. Humoral immune response will be quantified by anti-glycoprotein E (anti-gE) antibody titers. Patients will receive two doses of RZV. Outcomes include seroconversion and geometric mean titers six weeks after completion of the vaccination schedule, persistence of antibody titers at one year, and incidence of confirmed herpes zoster during follow-up.
This description comes directly from the study's public registry record.
Eloisa Bonfa, Full Professor · +55 11 3061-7492 · eloisa.bonfa@hc.fm.usp.br
Clovis Silva, Full Professor · +55 11 3061-7492 · clovisaasilva@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital das Clínicas | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07280741